Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Change in Receivables (2016 - 2025)

Immucell (ICCC) has disclosed Change in Receivables for 16 consecutive years, with $175943.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables fell 50.78% year-over-year to $175943.0, compared with a TTM value of $246853.0 through Sep 2025, down 44.32%, and an annual FY2024 reading of $1.6 million, up 271.56% over the prior year.
  • Change in Receivables was $175943.0 for Q3 2025 at Immucell, up from -$967602.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.5 million in Q4 2024 and bottomed at -$1.2 million in Q2 2022.
  • Average Change in Receivables over 5 years is $39892.9, with a median of $271974.0 recorded in 2021.
  • The sharpest move saw Change in Receivables plummeted 264.1% in 2022, then skyrocketed 896.63% in 2023.
  • Year by year, Change in Receivables stood at $271974.0 in 2021, then tumbled by 79.13% to $56770.0 in 2022, then soared by 465.08% to $320798.0 in 2023, then soared by 356.12% to $1.5 million in 2024, then crashed by 87.98% to $175943.0 in 2025.
  • Business Quant data shows Change in Receivables for ICCC at $175943.0 in Q3 2025, -$967602.0 in Q2 2025, and -$424708.0 in Q1 2025.